Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Regulatory News (ORPH)

  • There is currently no data for ORPH

Integumen Debt Conversion

1 May 2019 11:00

RNS Number : 7356X
Venn Life Sciences Holdings PLC
01 May 2019
 

1 May 2019

Venn Life Sciences Holdings Plc

("Venn" or the "Company")

Integumen plc ("Integumen") Debt Conversion - Related Party Transaction

Venn Life Sciences, an Integrated Drug Development Partner offering a combination of drug development expertise and clinical trial design and management to pharmaceutical, biotechnology and medical device organisations, announces, that following the approval of Integumen shareholders and under the terms of the Venn Debt Conversion Agreement the debt of £421,000 owed by Integumen, has been converted into 30,071,428 new Integumen ordinary shares at a price of 1.4 pence, conditional upon admission.

Separate to this conversion, Venn has sold 42,244,682 ordinary shares for a total consideration of €575,000. Following Admission of the conversion shares referred to above, Venn will hold 30,071,428 ordinary shares.

Venn has agreed that any disposal of Integumen ordinary shares held by them for the two years following Admission will be effected through Integumens broker so as to ensure an orderly market in the ordinary shares.

The debt conversion is a related party transaction for the purposes of Rule 13 of the AIM Rules for companies. As Tony Richardson is Integumens Chairman, the Chief Executive of Venn, and therefore is not considered to be independent for the purposes of considering and negotiating the Venn Debt Conversion Agreement. The Directors (other than Tony Richardson) consider, having consulted with Arden Partners plc, the Company's nominated adviser, that the terms of the Venn Debt Conversion Agreement and conversion by Venn are fair and reasonable in so far as its Shareholders are concerned.

 

Enquiries:

Venn Life Sciences Holdings plc Tel: +353 1 5499 341Tony Richardson, Chief Executive Officer

Arden Partners plc Tel: +44 (0)2076145900

John Llewellyn-Lloyd, Ruari McGirr, Benjamin Cryer

Davy (ESM Adviser and Joint Broker) Tel: +353 (0)1 679 6363Fergal Meegan / Matthew de Vere White (Corporate Finance)

 

 

DEFINITIONS

The following words and expressions shall have the following meanings in this document unless the context otherwise requires:

 

"Venn Debt Conversion Agreement"

the agreement dated 11 April 2019 between (1) the Company and (2) Venn to convert the Venn Debt into the Venn Debt Shares

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCSSASUFFUSEEI
Date   Source Headline
11th Mar 20217:00 amRNSJournal for Clinical Studies article publication
9th Mar 20217:00 amRNSNew contract win with Oxford BioTherapeutics
26th Feb 20214:58 pmRNSHolding(s) in Company
17th Feb 20219:00 amRNSEthics approval - COVID-19 Human Challenge Study
9th Feb 20213:57 pmRNSHolding(s) in Company
3rd Feb 20217:05 amRNSExercise of Investor Warrants & TVR
3rd Feb 20217:00 amRNSNew challenge study quarantine clinic
1st Feb 20217:00 amRNSContract extension with Carna Biosciences
21st Jan 20217:00 amRNSArticle published in Drug Discovery Today
20th Jan 20217:00 amRNSExpansion of volunteer recruitment centres
11th Jan 20217:00 amRNSFirst volunteer dosed in COVID-19 clinical trial
6th Jan 20214:29 pmRNSHolding(s) in Company
6th Jan 20217:00 amRNSContract renewal with top-3 pharmaceutical client
31st Dec 20207:00 amRNSRule 19.6(c) Confirmation
23rd Dec 20207:00 amRNSSuccessful completion of toxicology study
22nd Dec 20207:00 amRNSContract renewal with top-3 pharmaceutical client
14th Dec 20207:30 amRNSExercise of Share Options
14th Dec 20207:00 amRNSMHRA approval for nasal COVID-19 vaccine trial
7th Dec 20207:00 amRNSVenn Life Sciences contract wins
24th Nov 20207:00 amRNSDirectors Change
19th Nov 20207:00 amRNSCollaboration with HIC-VAC and Wellcome Trust
5th Nov 20207:00 amRNSNew £2.5m Influenza Challenge Study Contract Win
30th Oct 202011:00 amRNSPrice Monitoring Extension
30th Oct 20207:10 amRNSExercise of Share Options
30th Oct 20207:00 amRNSNew 2-year contract with a tier 1 German company
20th Oct 20207:00 amRNSContract Signed with UK Government
16th Oct 20208:47 amRNSStatement re further media comment
30th Sep 20207:00 amRNSInterim Results for 6 months ended 30 June 2020
28th Sep 20207:00 amRNSNew £4.3m Challenge Study Contract Win
24th Sep 20207:00 amRNSStatement re price movement and press speculation
23rd Sep 20204:41 pmRNSSecond Price Monitoring Extn
23rd Sep 20204:36 pmRNSPrice Monitoring Extension
22nd Sep 20207:30 amRNSExercise of Investor Warrants and Issue of Shares
22nd Sep 20207:00 amRNSNew Contract Win
7th Sep 20207:00 amRNShVIVO present at 2020 ERS International Congress
10th Aug 20207:00 amRNSMajor New Contract Win with Top 3 Pharma Company
4th Aug 20207:00 amRNSNew Contract Win with Carna Bioscience ("Carna")
28th Jul 20207:00 amRNSContract for COVID-19 Vaccine Trial
22nd Jul 202012:43 pmRNSResult of AGM
15th Jul 20207:00 amRNSOption to Acquire CHIMagents Limited
10th Jul 20208:00 amRNSEuronext Growth Dublin Notice
8th Jul 20207:00 amRNSUpcoming Investor Events
7th Jul 20207:10 amRNSExercise of Warrants
7th Jul 20207:00 amRNSAdditional Laboratory Services Contracts Signed
26th Jun 20201:05 pmRNSNotice of AGM
24th Jun 20207:00 amRNSResults for the year ended 31 December 2019
17th Jun 20209:33 amEQSHardman & Co Research: Open Orphan presenting at virtual Investor Forum on 9th July 2020
15th Jun 20207:00 amRNSPositive Phase I results published in The Lancet
12th Jun 20208:00 amRNSEuronext Growth Dublin Notice
11th Jun 202012:15 pmRNSResult of General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.